...
首页> 外文期刊>Hepatology research: the official journal of the Japan Society of Hepatology >Combination therapy of radiofrequency ablation and transarterial chemoembolization in recurrent hepatocellular carcinoma after hepatectomy compared with single treatment.
【24h】

Combination therapy of radiofrequency ablation and transarterial chemoembolization in recurrent hepatocellular carcinoma after hepatectomy compared with single treatment.

机译:肝切除术后复发性肝细胞癌的射频消融联合经动脉化学栓塞治疗与单药治疗相比。

获取原文
获取原文并翻译 | 示例

摘要

Aim: To assess the efficacy and safety of radiofrequency ablation (RFA) combined with transarterial chemoembolization (TACE) in recurrent hepatocellular carcinoma (HCC) after hepatectomy and to compare its outcome with a single modality. Method: We retrospectively studied 103 patients with recurrent HCCs after hepatectomy who were excluded from repeat hepatectomy. Of them, 81 patients were male and 22 were female (mean age 55.8 +/- 10.7 years; range, 30-80 years). According to treatment modality, these patients were divided into three groups: RFA was used as the sole first-line anticancer treatment in 37 patients (RFA group); TACE was used as the sole first-line anticancer treatment in 35 patients (TACE group). RFA followed by TACE was performed in 31 patients (combination group). There was no significant difference in clinical material between the three groups. Indices including treatment success rate, intrahepatic recurrence rate and survival were obtained for analysis and comparison. Results: The treatment success rate of the combination group was significantly higher than that of the TACE group (93.5 vs. 68.6%, P = 0.011). The intrahepatic recurrence rate of the combination group was significantly lower than that of the TACE group (20.7 vs 57.1%, P = 0.002) and the RFA group (20.7 vs 43.2%, P = 0.036). The overall 1-, 3- and 5-year survival rates were 73.9, 51.1 and 28.0% respectively in the RFA group; 65.8, 38.9 and 19.5% respectively in the TACE group; and 88.5, 64.6 and 44.3% respectively in the combination group. There was a significant difference in survival between the combination group and the TACE group (P = 0.028). Conclusion: RFA combined with TACE was more effective in treating recurrent HCC after hepatectomy compared to single RFA or TACE treatment. This combination therapy can thus be a valuable choice of treatment for recurrent HCC.
机译:目的:评估射频消融(RFA)联合经动脉化学栓塞术(TACE)在肝切除术后复发性肝细胞癌(HCC)中的疗效和安全性,并将其结果与单一方法进行比较。方法:我们回顾性研究了103例肝切除术后复发的HCC患者,这些患者被排除在重复性肝切除术之外。其中,男性81例,女性22例(平均年龄55.8 +/- 10.7岁;范围30-80岁)。根据治疗方式,将这些患者分为三组:RFA作为37例患者的唯一一线抗癌治疗(RFA组); TACE被用作35例患者的唯一一线抗癌治疗(TACE组)。在31例患者中(组合组)进行了RFA继之以TACE。三组之间的临床材料没有显着差异。获得包括治疗成功率,肝内复发率和存活率在内的指标用于分析和比较。结果:联合组的治疗成功率显着高于TACE组(93.5对68.6%,P = 0.011)。联合组的肝内复发率显着低于TACE组(20.7 vs 57.1%,P = 0.002)和RFA组(20.7 vs 43.2%,P = 0.036)。 RFA组的1年,3年和5年总生存率分别为73.9%,51.1和28.0%。 TACE组分别为65.8、38.9和19.5%;组合组分别为88.5%,64.6%和44.3%。联合治疗组与TACE治疗组的生存率存在显着差异(P = 0.028)。结论:与单次RFA或TACE治疗相比,RFA联合TACE治疗肝切除术后复发性HCC更有效。因此,这种联合治疗可能是复发性HCC治疗的宝贵选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号